Severe community-acquired pneumonia (SCAP) is a leading cause of intensive care unit (ICU) admission and mortality worldwide (1,2). Bacterial SCAP, distinct from viral or fungal infections, often triggers a dysregulated host response with systemic inflammation, endothelial dysfunction, and organ injury (3), providing a rationale for adjunctive immunomodulatory therapies such as corticosteroids (3,4).Corticosteroids have been widely investigated in pneumonia and sepsis because of their potential to attenuate cytokine release, preserve vascular integrity, and limit lung injury (4).Although the latest guidelines suggest or conditionally recommend corticosteroids in SCAP (1,5), evidence from randomized controlled trials (RCTs) remains inconsistent. Some studies demonstrated reductions in treatment failure or mortality (6)(7)(8), while others showed no significant clinical benefit (9,10). These divergent findings likely reflect variability in enrolled populations, causative pathogens, corticosteroid regimens, and study designs (11,12).Emerging data suggest that corticosteroids effects depend on systemic inflammation and treatment protocol (13,14), emphasizing the need for individualized rather than universal use. This paper revisits recent clinical trials of corticosteroids in SCAP, distills key lessons, examines challenges related to heterogeneous etiologies, inflammatory phenotypes, and therapeutic regimens, and outlines implications for current practice and future research.The pathophysiology of SCAP is marked by an excessive and dysregulated host immune response that contributes substantially to lung injury and systemic complications. During the acute phase, pathogen recognition leads to activation of nuclear factor κB (NF-κB) and other transcriptional pathways, with subsequent release of proinflammatory cytokines such as tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 (3,15,16). This hyperinflammatory cascade disrupts alveolar-capillary integrity, increases vascular permeability, and amplifies the risk of acute respiratory distress syndrome (ARDS) and multiorgan dysfunction (17,18).Corticosteroids exert pleiotropic immunomodulatory effects that directly target these mechanisms. By binding to cytoplasmic glucocorticoid receptors, they translocate to the nucleus and suppress transcription of proinflammatory genes while upregulating antiinflammatory mediators (4,15). Beyond cytokine suppression, corticosteroids stabilize endothelial and epithelial barriers, reduce leukocyte recruitment, and limit pulmonary edema (19)(20)(21). Preclinical studies suggest that corticosteroids may influence mitochondrial homeostasis and attenuate secondary tissue injury in non-infectious or in vitro injury models, although evidence in SCAP is lacking (22,23). Moreover, observational and mechanistic studies have linked higher systemic inflammation (e.g., elevated IL-6, CRP) with worse outcomes in pneumonia (15)(16)(17), and randomized trials suggest that the largest clinical gains from adjunctive corticosteroids occur in patients with a pronounced inflammatory response (8,13). These findings support the concept that modulation of the inflammatory milieu is the critical therapeutic target for corticosteroids in bacterial SCAP.Beyond their anti-inflammatory actions, corticosteroids modulate both innate and adaptive immunity by promoting macrophage efferocytosis, enhancing clearance of apoptotic cells, and fostering a shift toward reparative immune phenotypes (24). They also upregulate antiinflammatory mediators such as IL-10 and annexin A1, supporting resolution of inflammation and restoration of tissue homeostasis (25). In parallel, corticosteroids preserve endothelial integrity and regulate neutrophil trafficking, thereby limiting capillary leakage and alveolar injury. These actions indicate that corticosteroids not only suppress inflammation but also promote active disease resolution and tissue repair, providing a robust biological rationale for their use in bacterial SCAP characterized by severe systemic inflammation.Taken together, these biological insights provide the rationale for investigating corticosteroids as an adjunctive therapy in bacterial SCAP. They also show that the net clinical effect is determined not only by the intensity of inflammation but also by the timing, dose, and duration of corticosteroid administration in clinical practice (11,12).Over the last decade, several RCTs have evaluated adjunctive corticosteroids in patients with bacterial SCAP, but the results remain inconsistent (Table 1). The trial by Torres et al. demonstrated that methylprednisolone reduced treatment failure in patients with severe pneumonia and elevated C-reactive protein (CRP >150 mg/L), suggesting benefit in those with a heightened inflammatory response (8). More recently, the CAPE-COD trial reported a significant reduction in 28-day mortality and increased organ support-free days with hydrocortisone in ICU patients with SCAP, reinforcing the potential utility of early corticosteroid therapy (6). Similarly, a multicenter subgroup analysis of the APROCCHSS trial reported a shorter time to clinical stability and fewer complications in patients with SCAP and septic shock who were randomized to hydrocortisone plus fludrocortisone versus placebo (7).In contrast, other RCTs failed to demonstrate clear survival benefit. The ESCAPe trial found no significant effect of methylprednisolone on 60-day mortality or on any of the secondary outcomes (9). This study enrolled predominantly older male veterans, raising concerns about generalizability to broader ICU populations. Likewise, the REMAP-CAP adaptive platform trial screened more than 20,000 patients with pneumonia but ultimately randomized fewer than 1,000 and reporting neutral results for hydrocortisone with respect to mortality (10). Some analyses have underscored the considerable heterogeneity across trials (11,12). Key sources of...